Fatal combined immune hemolytic anemia after double cord blood transplantation in imatinib-resistant CML.
Rokicka
M
M
Styczynski
J
J
Michalewska
B
B
Torosian
T
T
Tomaszewska
A
A
Gronkowska
A
A
Pogorzala
M
M
Wysocki
M
M
Lakomy
M
M
Wiktor-Jedrzejczak
W
W
D000743:Anemia, Hemolytic / Q000150:complications / Q000276:immunology*; D000744:Anemia, Hemolytic, Autoimmune / Q000209:etiology*; D000888:Antibodies, Anti-Idiotypic / Q000097:blood; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D036101:Cord Blood Stem Cell Transplantation / Q000009:adverse effects*; D016572:Cyclosporine / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D017809:Fatal Outcome; D005260:Female; D006086:Graft vs Host Disease / Q000517:prevention & control; D006801:Humans; D000068877:Imatinib Mesylate; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015466:Leukemia, Myeloid, Chronic-Phase / Q000150:complications / Q000628:therapy; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D013156:Splenectomy; D065227:Transfusion Reaction; D019172:Transplantation Conditioning; D055815:Young Adult
D000888:Antibodies, Anti-Idiotypic; D000970:Antineoplastic Agents; D001549:Benzamides; D007166:Immunosuppressive Agents; D010879:Piperazines; D011743:Pyrimidines; D016572:Cyclosporine; D000068877:Imatinib Mesylate